Generation Bio Co(GBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.35 | Insider Own | 23.7% | Shs Outstand | 6.7M | Perf Week | - |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 84.17% | Insider Trans | - | Shs Float | 5.2M | Perf Month | -4.47% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -6.85 | Inst Own | 38.8% | Short Float | 0.15% | Perf Quarter | -1.11% |
| Income | -0.06B | P/S | 2.36 | EPS this Y | 34.42% | Inst Trans | -6.13% | Short Ratio | 0.09 | Perf Half Y | -16.43% |
| Sales | 0.02B | P/B | 0.71 | EPS next 5Y | 53.82% | ROA | -33.79% | Short Interest | 0.01M | Perf YTD | -5.99% |
| Book/sh | 7.51 | P/C | 0.4 | EPS past 3/5Y | 2.26% -8.29% | ROE | -80.81% | 52W High | -34.88% ($8.20) | Perf Year | -33.72% |
| Cash/sh | 13.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | -89.08% | 52W Low | 77.76% ($3.00) | Perf 3Y | -92.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.32% | Gross Margin | 68.24% | Volatility(W/M) | 4.65% 2.78% | Perf 5Y | -98.38% |
| Dividend TTM | - | EV/Sales | -1.8 | Sales Y/Y TTM | -17.82% | Oper. Margin | -512.53% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.44 | EPS Q/Q | 64.28% | Profit Margin | -410.13% | RSI (14) | 39.71 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.44 | Sales Q/Q | -78.9% | SMA20 | -4.85% ($5.61) | Beta | 2 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.52 | Earnings | 2025/11/5 | SMA50 | -2.7% ($5.49) | Rel Volume | 0 | Prev Close | $5.34 |
| Employees | 115 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | 73.97% 141.52% | SMA200 | 5.22% ($5.08) | Avg Volume(3M) | 0.08M | Price | $5.34 |
| IPO | 2020/6/12 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🔬 Generation Bio (GBIO) is a biotechnology company that researches and develops non-viral gene therapies capable of avoiding immune responses and enabling repeat dosing, along with gene delivery platforms for the precise delivery of these therapies to the liver and other major organs.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
GBIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +34.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $236. Peers typically go for $204.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 38.8%.
Tap to view numbers
It ranks #441 of 596 in the industry
Based on market cap of $36M.
EXOZ#440 eXoZymes Inc $37M PER - GBIO#441 Generation Bio Co $36M PER - 
NNVC#441 NanoViricides Inc $36M PER - 
LITS#442 Lite Strategy Inc $35M PER - 
CRVO#443 CervoMed Inc $35M PER - 
FAQ
What kind of company is GBIO?
GBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GBIO?
The market cap of GBIO is approximately $36M, ranking 5,062 within its sector.
What is the 52-week high and low for GBIO?
GBIO has recorded a 52-week high of $8.20 and a low of $3.00.
